A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy
Stereotactic body radiation therapy has emerged as a promising alternative to brachytherapy, delivering high doses to tumors with precision while sparing surrounding organs. This systematic review evaluates the role of SBRT as a boost for patients who are ineligible for brachytherapy. A total of 17...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203811614818304 |
|---|---|
| author | Iozsef Gazsi Loredana G. Marcu |
| author_facet | Iozsef Gazsi Loredana G. Marcu |
| author_sort | Iozsef Gazsi |
| collection | DOAJ |
| description | Stereotactic body radiation therapy has emerged as a promising alternative to brachytherapy, delivering high doses to tumors with precision while sparing surrounding organs. This systematic review evaluates the role of SBRT as a boost for patients who are ineligible for brachytherapy. A total of 17 studies, involving 288 patients, were analyzed, focusing on dosimetric parameters and toxicity. The radiation regimens varied in dose and fractionation schedules, with external beam doses ranging from 44 to 61.6 Gy, and SBRT boost doses ranging from 5 to 30 Gy. The total EQD<sub>2</sub> doses were between 50.5 and 92.4 Gy. The results indicate adequate tumor control with SBRT, with local control rates ranging from 57% to 95.5%. The acute genitourinary and gastrointestinal toxicities were mostly grade 1 or 2, while late toxicities were less common. The overall survival rates varied between 34% and 96%. These results suggest that SBRT boost offers a viable option for cervical cancer patients ineligible for brachytherapy, with acceptable toxicity and promising survival outcomes. Nevertheless, the scarcity of data, which mainly originate from small studies with patients having varied stages of disease, as well as the lack of long-term follow up with SBRT, should encourage clinicians to utilize brachytherapy whenever suitable as a boost in these patient cohorts. |
| format | Article |
| id | doaj-art-500abd8aa7c84133a6b534be3f2f3479 |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-500abd8aa7c84133a6b534be3f2f34792025-08-20T02:11:25ZengMDPI AGCurrent Oncology1198-00521718-77292025-03-0132317010.3390/curroncol32030170A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from BrachytherapyIozsef Gazsi0Loredana G. Marcu1Faculty of Physics, West University of Timisoara, 300223 Timisoara, RomaniaFaculty of Informatics & Science, University of Oradea, 410087 Oradea, RomaniaStereotactic body radiation therapy has emerged as a promising alternative to brachytherapy, delivering high doses to tumors with precision while sparing surrounding organs. This systematic review evaluates the role of SBRT as a boost for patients who are ineligible for brachytherapy. A total of 17 studies, involving 288 patients, were analyzed, focusing on dosimetric parameters and toxicity. The radiation regimens varied in dose and fractionation schedules, with external beam doses ranging from 44 to 61.6 Gy, and SBRT boost doses ranging from 5 to 30 Gy. The total EQD<sub>2</sub> doses were between 50.5 and 92.4 Gy. The results indicate adequate tumor control with SBRT, with local control rates ranging from 57% to 95.5%. The acute genitourinary and gastrointestinal toxicities were mostly grade 1 or 2, while late toxicities were less common. The overall survival rates varied between 34% and 96%. These results suggest that SBRT boost offers a viable option for cervical cancer patients ineligible for brachytherapy, with acceptable toxicity and promising survival outcomes. Nevertheless, the scarcity of data, which mainly originate from small studies with patients having varied stages of disease, as well as the lack of long-term follow up with SBRT, should encourage clinicians to utilize brachytherapy whenever suitable as a boost in these patient cohorts.https://www.mdpi.com/1718-7729/32/3/170stereotactic body radiation therapygynecologic cancertumor controltoxicity |
| spellingShingle | Iozsef Gazsi Loredana G. Marcu A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy Current Oncology stereotactic body radiation therapy gynecologic cancer tumor control toxicity |
| title | A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy |
| title_full | A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy |
| title_fullStr | A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy |
| title_full_unstemmed | A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy |
| title_short | A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy |
| title_sort | systematic review of sbrt boost for cervical cancer patients who cannot benefit from brachytherapy |
| topic | stereotactic body radiation therapy gynecologic cancer tumor control toxicity |
| url | https://www.mdpi.com/1718-7729/32/3/170 |
| work_keys_str_mv | AT iozsefgazsi asystematicreviewofsbrtboostforcervicalcancerpatientswhocannotbenefitfrombrachytherapy AT loredanagmarcu asystematicreviewofsbrtboostforcervicalcancerpatientswhocannotbenefitfrombrachytherapy AT iozsefgazsi systematicreviewofsbrtboostforcervicalcancerpatientswhocannotbenefitfrombrachytherapy AT loredanagmarcu systematicreviewofsbrtboostforcervicalcancerpatientswhocannotbenefitfrombrachytherapy |